Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility [PDF]
, 2003 TG St Pierre
openalex +1 more source
Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemia [PDF]
, 2004 Annita Kolnagou +4 more
openalex +1 more source
Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major [PDF]
, 2005 Caterina Borgna‐Pignatti
openalex +1 more source
The Role of Deferiprone in Iron Chelation [PDF]
New England Journal of Medicine, 2019 Banerjee, G, Sammaraiee, Y, Werring, DJ
openaire +4 more sources
Risks of aluminium exposure during pregnancy [PDF]
, 2000 És ben conegut que l'alumini és potencialment neurotòxic. En els darrers anys s'ha plantejat si l'exposició dietètica i mediambiental a l'alumini podia causar toxicitat en el desenvolupament dels mamífers.
Colomina i Fosch, Maria Teresa +2 more
core
Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions [PDF]
, 2006 Ellis J. Neufeld
openalex +1 more source
Use of the oral chelator deferiprone in the treatment of iron overload in patients with Hb H disease [PDF]
, 2006 Joyce C. W. Chan +6 more
openalex +1 more source
Adherence to desferrioxamine and deferiprone and the impact of deferiprone co‐prescription in thalassaemia major patients. Does the addition of deferiprone improve adherence? [PDF]
British Journal of Haematology, 2008 Robert Lindeman, Giselle L Kidson-Gerber
openaire +3 more sources
FDA panel recommends approval of deferiprone [PDF]
Canadian Medical Association Journal, 2011 Earlier this month, Tony Viola, president of the Cooley’s Anemia Foundation, a New York City, New York-based nonprofit advocacy group for people with thalassemia, boarded a bus headed to the United States Food and Drug Administration’s (FDA) Silver Springs, Maryland campus, telling ...
openaire +2 more sources
Oral iron chelation therapy with deferiprone in patients with Thalassemia Major [PDF]
, 2009 OBJECTIVE: To determine the efficacy and adverse effects of deferiprone in patients with Thalassemia Major. METHODS: A prospective case series study was conducted at the Fatimid Foundation Blood Bank and Haematological Diseases center Lahore.
Adil, Salman +3 more
core +1 more source